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ABSTRACT 
Hepatic ischemia-reperfusion (I/R) injury is a complex phenomenon occuring in response to 
interruption of the liver’s blood and oxygen supply and the subsequent restoration of blood 
flow and tissue oxygenation. Techniques to reduce blood loss and other intra-operative 
manoeuvers during liver resection can cause hepatic I/R injury. I/R injury to the liver is also 
unavoidable during the transplantation procedure. This directly impacts liver viability with 
consequences ranging from mild organ dysfunction to hepatic failure. Hepatic I/R injury has 
been extensively studied but there is still much to be understood.  
Paper I studied the effect of portal triad clamping (PTC) on hepatic metabolism in patients 
undergoing liver resection using intrahepatic microdialysis to monitor glucose, lactate and 
pyruvate as markers of ischemia and glycerol as a marker of cell membrane damage. The 
lactate/pyruvate ratio (L/Pr) was also calculated. PTC induced considerable alterations, with 
anaerobic metabolism and increased glycogenolysis manifested by increased levels of 
glucose, lactate and L/Pr and cell membrane damage evidenced by increased levels of 
glycerol 
Papers II and III were methodological studies of hepatic microdialysis in pig models. We 
could show that microdialysis catheters with membrane cut-off of 20 and 100 kDa could be 
used equally in hepatic microdialysis for monitoring the products of glucose metabolism and 
glycerol. However, microdialysis performed using a catheter placed directly in the middle 
hepatic vein was not equivalent to direct intrahepatic monitoring of the same metabolites. 
Paper IV investigated the effects of warm I/R injury induced by PTC on hepatic morphology 
at the ultrastructural level and on the expression of the thioredoxin and glutaredoxin redox 
systems. On electron microscopy, a significant loss of the liver sinusoidal endothelial cell 
(LSEC) lining was observed and a decrease of hepatocyte microvilli. Hepatocellular 
morphology was well preserved apart from the appearance of crystalline mitochondrial 
inclusions. After reperfusion the LSEC lining showed signs of reactivation. No significant 
changes were observed in the TRX and GRX redox systems. 
Paper V explored the value of L/Pr measured by microdialysis as a marker for ischemic 
complications in 45 patients undergoing liver transplantation (LT). Raised L/Pr defined 
according to protocol were identified in 24 patients but none were predictive of clinically 
significant ischemic complications. L/Pr is thus not a reliable marker of clinically significant 
ischemic events after LT. 
Paper VI evaluated microdialysis as a postoperative monitoring tool for detection of acute 
cellular rejection (ACR) in patients undergoing LT. ACR was diagnosed in 33 of 71 
transplanted patients. Results revealed metabolic patterns indicating a possible relation 
between the severity of primary I/R injury and the development of ACR. 
In conclusion, warm ischemia induced by PTC causes significant alterations in hepatic 
metabolism and ultrastructure. L/Pr measured by microdialysis is not a reliable marker for 
detecting clinically significant ischemic complications early after LT. Primary I/R injury 
experienced by the organ during the LT procedure may be associated with the development 
of ACR. It may be possible to monitor larger molecules using microdialysis with 100kDa 
catheters without affecting the monitoring of small molecules. To get reliable results when 
monitoring hepatic metabolism by microdialysis the catheter should be placed 
intrahepatically. 
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1 INTRODUCTION 
Ischemia occurs when an organ or tissue is deprived of its blood supply and with it a lack of 
oxygen and nutrients. The cellular metabolic machinery is disrupted and when the blood 
supply is restored a compounding reperfusion injury occurs. This biphasic phenomenon is 
referred to as ischemia-reperfusion (I/R) injury [1]. Operative manoeuvres employed during 
liver resection, including those used to reduce blood loss can lead to hepatic I/R injury of 
the liver remnant. On the other hand, I/R injury is inherent to the process of liver 
transplantation (LT) and occurs during organ procurement, storage and the transplantation 
surgery. I/R injury in the liver is one of the most significant causes of morbidity and 
mortality after liver resection surgery and transplantation [2-5].  
Studying the effects of I/R injury on liver metabolism could be of immense value with 
clinical implications for both liver resection surgery and transplantation. This information 
can be useful to understand the effect of various operative manoeuvres on hepatic 
metabolism and to establish the safety of various clamping manoeuvres during liver 
surgery. It may help to correlate metabolic alterations with clinical outcomes after LT 
especially in situations with extended ischemia times or marginal liver grafts. It may further 
help to modify intraoperative strategies and possibly postoperative management to 
attenuate the effects of hepatic I/R injury.  
Hepatic I/R injury involves a complex cascade of cellular and humoral interactions 
eventually leading to cellular injury [6-8]. Hepatic I/R injury has been extensively studied 
and there is a vast literature on the topic but there is still much to be understood partly due to 
the complexity of the metabolic milieu of the liver and the cellular and molecular 
mechanisms involved [9, 10]. The hepatic response to ischemia and reperfusion may not 
necessarily be similar to the mechanisms seen in other organ systems.  
The aim of this doctoral thesis is to contribute to the better understanding of the 
phenomenon of hepatic I/R injury. To this end, both clinical and experimental studies using 
techniques like microdialysis, electron microscopy (EM) and gene expression analysis of 
redox proteins in human subjects and animals have been performed.  
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2 BACKGROUND 
2.1 LIVER ANATOMY  
Since antiquity, the liver has held a central position in human awareness and was often 
considered to be the seat of emotions. The legend of Prometheus from Greek mythology 
reveals the ancient understanding that the liver has the unique capacity to regenerate itself 
[11]. It is this remarkable regenerative potential of the liver that has made possible the range 
and scope of liver surgery and transplantation.  
 
Figure 1. Segmental and vascular anatomy of the liver. 
From: Abdel-Misih SR, Bloomston M. Liver anatomy. Surg Clin North Am. 2010 
Aug;90(4):643-53. doi: 10.1016/j.suc.2010.04.017. 
Reprinted with permission from Elsevier. 
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Weighing approximately 2-3% of the total body weight in a normal human adult, the liver is 
the largest solid organ in the body. Suspended by peritoneal reflections or ligaments, the liver 
lies beneath the diaphragm to the right of the upper abdomen. The gallbladder lies on its 
inferior surface and drains via the cystic duct into the bile duct. The liver’s dual blood supply 
comprising of the portal vein and the hepatic artery enters the organ through the ‘porta 
hepatis’ at the liver hilum [12]. The portal vein supplies 75% of the blood flow but the 
hepatic artery delivers half of the liver’s oxygen supply. 
Historically, the liver was anatomically divided into right and left lobes divided by the 
falciform ligament and the ligamentum teres as it enters the liver. This classical division 
however has little relation with the functional anatomy of the liver first described by the 
French surgeon and anatomist Claude Couinaud in the 1950s [13]. Based on third-order 
distribution of the portal pedicles, the liver was divided into 4 sectors and 8 segments (Figure 
1). Each segment has its own inflow, both arterial and portal, as well as bile drainage. The 
Cantlie line passing from the middle hepatic vein to the gallbladder divides the right and left 
lobes of the liver [14]. The caudate lobe (segment 1) straddles the retrohepatic vena cava 
behind the porta hepatis. 
 
Figure 2. Microscopic anatomy of the liver depicting the hepatocytes, portal tracts and 
the sinusoidal spaces.  
From: Abu Rmilah A, Zhou W, Nelson E, Lin L, Amiot B, Nyberg SL. Understanding the 
marvels behind liver regeneration. Wiley Interdiscip Rev Dev Biol. 2019 May;8(3):e340. doi: 10.1002/wdev.340. 
Reprinted with permission from John Wiley and Sons. 
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The ‘portal tracts’ comprising portal vein and hepatic artery divisions, bile ducts, lymphatic 
vessels and nerve fibers radiate from the hilum and course through the liver. Within the 
liver the portal and arterial blood mix and are distributed though the fenestrated sinusoids. 
The sinusoidal spaces are lined by hepatocytes (liver cells) arranged in cords, one or two cells 
thick and are lined by endothelial cells and Kupffer cells (KC), the latter belonging to the 
macrophage-phagocytic system. The liver sinusoidal endothelial cells (LSEC) form a 
fenestrated lining allowing easy exchange of molecules between blood and the hepatocytes 
(Figure 2). This exchange takes place through the ‘space of Disse’, which is a compartment 
between the LSEC and hepatocytes. Nutrients in the blood coming from the intestine diffuse 
through this space and equilibrate with the extracellular fluid [15]. Liver-associated 
lymphocytes or pit cells also line the sinusoids [16]. The sinusoidal blood then courses 
through hepatic venules finally joining to form the 3 main hepatic veins, which leave the liver 
to carry blood into the inferior vena cava and on to the heart.  
 
2.2 GLUCOSE METABOLISM IN THE LIVER 
The liver plays a central role in glucose metabolism. The various pathways of glucose 
metabolism, including glycogenesis, glycogenolysis, glycolysis and gluconeogenesis are 
central to this vital function of the liver in glucose homeostasis. Carbohydrates are broken 
down by digestive processes in the gut into simple sugars, the monosaccharides glucose, 
galactose and fructose and reach the liver via the portal vein. Glucose is the main product of 
this breakdown and along with glucose from the systemic circulation via the hepatic artery 
reaches finally to the fenestrated sinusoids in the liver. Here, a passive equilibration occurs 
with the hepatic parenchymal interstitial fluid and glucose enters passively into the 
hepatocytes along the concentration gradient via the bidirectional glucose transporter-2 or 
GLUT2 [17]. Once in the hepatocyte, free glucose is then phosphorylated to glucose 6-
phosphate by the enzyme glucokinase. Glucose 6-phosphate may be metabolized in 3 ways, 
isomerization into glucose 1-phosphate and uridine diphosphate-glucose (UDP-glucose), 
conversion to fructose 6-phosphate or oxidation to initiate the pentose phosphate pathway 
(Figure 3) [18]. 
UDP-glucose is the direct glucose donor for glycogen synthesis or the process of 
glycogenesis, which is the most important pathway of glucose utilization in the liver. After a 
meal, insulin is released from the pancreas and most glucose entering the liver cells is 
converted to and stored as glycogen to create a hepatic reserve that can be used during 
fasting. Glycogenesis may also proceed utilizing glucose derived from gluconeogenesis and 
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this represents the indirect pathway. The adult human liver can store up to 100-120 grams of 
glycogen. During fasting, when the insulin levels decrease, and glucagon levels rise, 
glycogen is broken down by the process called glycogenolysis. The enzymes glycogen 
phosphorylase and glycogen debranching enzyme are those responsible for glycogenolysis. 
Glucose molecules are sequentially removed from the glycogen branches and exit the 
hepatocytes by passive diffusion via the GLUT2 channels [18].  
 
Figure 3. Glucose pathways in the liver. 
From: Adeva-Andany MM, Pérez-Felpete N, Fernández-Fernández C, Donapetry-García C, 
Pazos-García C. Liver glucose metabolism in humans. Biosci Rep. 2016 Nov 
29;36(6). pii: e00416. doi: 10.1042/BSR20160385. 
Reprinted according to CC-BY-4.0. 
 
The liver has the unique ability to release glucose into the blood stream when needed. This is 
achieved by the process of glycogenolysis as described above but also by de novo synthesis, 
referred to as gluconeogenesis. Glycogenolysis is responsible for the initial glucose 
production in times of need but when glycogen stores are depleted gluconeogenesis takes 
over as the source of hepatic glucose output [19]. In the liver, the gluconeogenesis pathway is 
used to synthesize glucose from fructose, glycerol, lactate and alanine. 
Glucose is also oxidized in the liver to yield energy through the process of glycolysis that 
takes place in the hepatocyte cytosol. The tricarboxylic acid (TCA) or Kreb’s cycle and the 
respiratory chain that follows next, occur in the mitochondria. Glycolysis does not need 
oxygen to proceed and it produces two molecules of adenosine triphosphate (ATP) and 
Nicotinamide Adenine Dinucleotide (NADH) per molecule of glucose. The end product of 
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glycolysis is pyruvate (two molecules), which in the presence of oxygen moves into the inner 
mitochondrial matrix to be decarboxylated by the enzyme pyruvate dehydrogenase [20]. 
Acetyl CoA formed in this reaction enters the aerobic TCA cycle. During the TCA cycle, 
high-energy molecules, including ATP, NADH, and flavin adenine dinucleotide 
hydroquinone (FADH2), are produced. Enzymatic reactions occurring in the inner 
mitochondrial membrane process NADH and FADH2 to generate ATP.  This electron 
transport chain (ETC) yields a net total of 36 ATPs for every glucose molecule [21]. 
A small percentage of cytosolic pyruvate is metabolized to lactate to yield two ATP 
molecules per glucose molecule. Pyruvate is converted into lactate by the enzyme lactate 
dehydrogenase. Lactate produced in this way in other tissues like muscle can only be 
metabolized in the liver where it is converted back to glucose via the Cori cycle [22]. Here, 
six molecules of ATP are utilized per glucose molecule generated. The glucose which is 
released into the blood by the liver can then be used by organs like the brain, muscle and the 
red blood cells for energy metabolism. 
 
Figure 4. Schematic representation of glucose metabolism in the liver. 
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2.3 LIVER RESECTION AND TRANSPLANTATION 
2.3.1 Liver resection surgery 
Since Couinaud’s description of the internal anatomy of the liver in the 1950s, the realization 
that the liver could be safely and successfully resected began to be established. Up until the 
1980s it was still considered a dangerous operation with high morbidity and mortality and it 
took several decades for liver surgery to come into its own [23, 24]. The relative anatomic 
inaccessibility of the liver, it’s concealed vascular anatomy and its immense vascularity has 
contributed to the complexity associated with liver surgery. A better understanding of the 
liver’s anatomy, improved surgical techniques and advancements in perioperative 
management, have led to an exponential increase in the number and complexity of liver 
resections being performed for a variety of indications including primary and secondary 
hepatic malignancies [25-28]. With the modern multidisciplinary approach including 
effective oncologic treatment strategies, short- and long-term outcomes after liver resection 
for malignancy have improved [29]. More patients nowadays undergo complex and extended 
resections on livers exposed to chemotherapy than ever before.  
The prerequisite for performing a liver resection is to preserve adequate volume of liver 
parenchyma to maintain function, preserve vascular inflow (portal venous and hepatic 
arterial) and outflow from the liver remnant to the vena cava and maintain a functioning 
biliary drainage. Liver function is of particular concern when operating on patients with 
hepatic fibrosis, steatosis, cirrhosis or livers exposed to chemotherapy [30-33]. Unfortunately, 
the estimation of preoperative liver function is an unexacting science and it is still difficult to 
accurately prognosticate the consequences of liver resection in a patient with compromised 
liver function [34]. Furthermore, the percentage of remnant liver volume correlates poorly 
with remnant liver function. 
2.3.2 Bleeding during liver resection and clamping manoeuvres 
Intraoperative bleeding is one of the major risks of liver surgery. Apart from being a cause of 
mortality, significant blood loss and transfusion has been related to increased morbidity and 
even tumor recurrence after liver resection [35, 36]. A number of technical operative 
refinements like the use of specialized instruments such as Cavitron Ultrasonic Surgical 
Aspirator (CUSA), Water Jet, LigaSure, TissueLink and intraoperative anaesthesiologic 
management like low central venous pressure (CVP) during parenchymal transection has 
been shown to reduce bleeding [28, 37]. In addition to the above, several techniques of inflow 
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occlusion can be used to reduce hepatic bleeding. The most commonly used in clinical 
practice is the classical ‘Pringle manoeuvre’ or ‘Portal triad clamping’ (PTC) first described 
in 1908 by James Hogarth Pringle [38, 39]. PTC is most commonly performed by placing a 
vascular clamp or a soft cotton band to occlude the hepatoduodenal ligament and thus the 
vascular inflow of the liver (Figure 5). PTC is usually applied for 15 minute-periods during 
parenchymal transection and released for 5 minutes.  
 
Figure 5. The Pringle manoeuvre. 
From: François Cauchy, Olivier Scatton, Jacques Belghiti, Olivier Soubrane. Vascular isolation techniques in 
hepatic resection. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set  
Reprinted with permission from Elsevier. 
 
Total hepatic vascular exclusion (THVE) is an additional method used to control bleeding 
during liver surgery and involves complete vascular inflow and outflow control. However, 
when applied for a prolonged time it can be associated with severe hemodynamic instability 
[39, 40]. As opposed to THVE, selective hepatic vascular exclusion (SHVE) is another 
technique wherein the vena cava is not clamped but the hepatic veins are clamped selectively 
thereby avoiding the hemodynamic consequences of THVE [41]. THVE and SHVE are 
however not used routinely in clinical practice. While these clamping manoeuvres may be 
effective in reducing blood loss they cause hepatic ischemia and subsequent reperfusion 
injury, I/R injury to the remnant liver. Depending on factors like the duration of clamping, 
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underlying quality of the hepatic parenchyma, volume of blood loss and other factors, the 
consequences of this injury may range from mild organ dysfunction to fulminant post-
hepatectomy liver failure (PHLF) [3, 6, 42, 43]. Although PTC has been widely used to 
reduce blood loss during liver resection, concerns about I/R injury in patients with 
compromised liver function have led to its selective use [44, 45]. The newer technical tools 
used for liver parenchymal transection have probably decreased bleeding and as a 
consequence reduced the need for PTC, but it is still an effective method to reduce blood loss 
in difficult or urgent surgical situations.  
 
2.3.3 Liver transplantation 
A team led by Dr. Thomas Starzl performed the first human LT in Denver, Colorado, USA in 
1963 [46]. Since then LT has become the gold standard for treatment of end stage liver 
disease of most etiologies, several metabolic disorders, some hepatic malignancies and 
uncommonly fulminant acute liver failure [47, 48]. As a clinical practice, LT is a science of 
multidisciplinary surgery and medicine and central to achieving optimal outcomes after LT, is 
the effective management of immunosuppression [49]. The quality of the donor graft can be 
assessed by several indexes. Age, liver fat percent, graft volume and ischemia time are some 
of the parameters used and donor grafts of borderline quality are referred to as “marginal” or 
“extended criteria” donors [50, 51]. The transplantation procedure involves donor 
hepatectomy, perfusion, transport, graft preparation and in the recipient, total hepatectomy 
and graft implantation with reconstruction of the liver vessels and biliary drainage.  A veno-
venous bypass is not routinely used during LT nowadays; instead, the ‘piggyback technique’ 
is preferred. I/R injury is thus unavoidable in the context of the LT procedure. 
2.3.4 Graft dysfunction after liver transplantation 
The presentation of graft dysfunction post-LT is a challenging entity, difficult to detect 
clinically and by laboratory and radiological investigations. Blood liver biochemistry is the 
mainstay for detection and monitoring of complications in the post-transplant period and is 
often the first indication that the liver graft is not functioning optimally. However, these are 
very non-specific and can lead to a delay in detection and institution of appropriate treatment. 
The main causes of graft dysfunction are summarized in Figure 6 and the spectrum of 
complications can range from a mild biochemical derangement to life threatening liver failure 
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and graft loss [52]. For the purposes of this thesis, ischemic vascular complications and acute 
cellular rejection (ACR) will be discussed individually. 
 
Figure 6. Complications and causes of graft dysfunction after liver transplantation 
 
2.3.5 Vascular complications after liver transplantation 
Hepatic artery thrombosis (HAT) and portal vein thrombosis (PVT) are the most important of 
the vascular complications occurring after LT [52]. HAT is the most common and the most 
dangerous of these and occurs in around 2-9% of LT patients [53]. It remains one of the 
foremost causes of early graft loss. The biliary tree is entirely dependent on hepatic arterial 
blood flow and HAT affects not only the graft globally but the bile ducts in particular. Even if 
HAT resolves, long term biliary complications may lead to secondary biliary cirrhosis and 
graft failure [54]. HAT can be differentiated into early and late. Early HAT usually presents 
within the first week post-LT and may present with massive liver enzyme elevations, 
coagulopathy, bile leak and signs of acute liver failure but early HAT can also be 
biochemically and clinically silent [55]. Late HAT on the other hand may present years after 
LT with gradually worsening liver function and recurrent cholangitis. Timely detection of 
HAT is thus of paramount importance and usually starts with Doppler ultrasound 
examinations on biochemical and clinical suspicion. This is usually followed up with 
computed tomography (CT) or magnetic resonance imaging (MRI). The management options 
include surgical or interventional radiological revascularization, retransplant, or conservative 
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treatment [55, 56]. PVT has a reported incidence of up to 7% of grafts. PVT however has a 
more indolent course but may present with portal hypertension or acutely with graft failure 
and significant hepatic necrosis [52]. 
2.3.6 Acute Cellular Rejection  
The liver is said to be immunologically privileged; however ACR is relatively common and 
affects approximately 20 to 60% of LT patients and is usually detected within the first 6 
weeks after LT [57]. The clinical and biochemical manifestations of ACR are non-specific 
and percutaneous liver biopsy is often required to verify the diagnosis [58]. Apart from the 
risks associated with the biopsy this may by itself delay diagnosis and treatment. ACR is 
usually treated with steroid boluses and higher doses of basic immunosuppression. ACR is a 
known risk factor for the development of chronic rejection (CR), which in turn may lead to a 
progressive immune-mediated damage to the bile ducts resulting in a cholestatic graft 
dysfunction and graft loss needing retransplantation [59]. Timely detection of ACR is thus of 
paramount importance for preserving graft function and improving outcomes after LT. 
 
2.4 HEPATIC ISCHEMIA-REPERFUSION INJURY 
Hepatic I/R injury occurs when the liver or part of it is deprived of blood. The initial 
ischemic insult (ischemia) is compounded by the inflammatory burst on restoration of the 
blood supply (reperfusion). There is a vast literature on the topic of I/R injury in general, 
but the mechanisms involved in hepatic I/R injury are still poorly understood. It is a 
biphasic phenomenon comprising a complex interaction of cellular and humoral events 
finally leading to cellular damage. The 2 distinct phases are the initial stage of ‘Ischemic 
injury’, characterized by a mainly local metabolic derangement due to lack of oxygen 
supply, resulting in glycogen consumption, ATP depletion and cell death. The next phase of 
‘Reperfusion injury’ combines not only a metabolic derangement but also a profound 
immune mediated inflammatory response, which generates damaging free radicals or 
reactive oxygen species (ROS), which are directly toxic [60].  
Hepatic ischemia is also classified as ‘warm’ or ‘cold’. Warm ischemia occurs ‘in situ’ in 
the setting of liver resection, transplantation, trauma, and shock when the blood supply to 
the liver is interrupted. On the other hand cold ischemia occurs typically ‘ex vivo’ during 
organ preservation after flushing the liver with cold preservation solutions and 
transportation before LT [61]. While both types of injury share common mechanisms there 
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are some fundamental differences between them. For example, the existing evidence is that 
warm I/R injury mainly affects hepatocytes, whereas cold I/R injury is initiated by damage 
to the LSEC and microcirculation [9]. However, both hepatocyte and LSEC injury occur in 
warm and cold ischemia. Indeed, both types of I/R injury have in common the activation of 
neutrophils and KC, generation of cytokines and chemokines, production of ROS, 
upregulation of adhesion molecules and lymphocyte/monocyte infiltration [60, 62].  
 
 
Figure 7. Schematic representation of events in hepatic ischemia-reperfusion injury 
From: Datta G, Fuller BJ, Davidson BR. Molecular mechanisms of liver ischemia 
reperfusion injury: insights from transgenic knockout models. World J 
Gastroenterol. 2013 Mar 21;19(11):1683-98. doi: 10.3748/wjg.v19.i11.1683. 
Reprinted according to CC-BY-4.0. 
 
With the onset of ischemia, the oxygen tension in the liver tissue decreases and the ensuing 
mitochondrial dysfunction causes metabolism to shift from aerobic to anaerobic. The 
microenvironment becomes acidic and the production of high energy ATP decreases, 
becoming insufficient to meet the energy needs of cellular metabolism [63]. This ATP 
deficiency causes dysfunction of the ion pumps of the cell membrane. Sodium and calcium 
ions flood into the cells and their intracellular concentration increases. The cells swell, and 
the increased intracellular calcium activates phospholipases, which degrade the cellular 
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membrane phospholipids [63-65]. This results in a disruption of the cell membrane and 
intracellular contents leak out into the interstitial space including cell membrane glycerol. 
The cell death that occurs at this stage is mainly by apoptosis but if ischemia is prolonged 
necrosis will occur. Indeed, the acidic environment serves to delay necrosis and it is the 
onset of reperfusion injury that initiates the cellular necrosis [66, 67]. The cell swelling in 
combination with the imbalance between nitric oxide (NO) and endothelin production 
(relative excess of endothelin), leads to the narrowing of lumen of the sinusoidal spaces 
resulting in a microcirculatory dysfunction. This reduction in sinusoidal diameter and blood 
flow contributes to platelet and neutrophil accumulation and further compromise of the 
blood flow on reperfusion [9]. 
2.4.1 Cellular interactions in hepatic I/R injury 
Hepatocytes, LSEC, KC, platelets and neutrophils are the major cellular components 
involved in the initiation and progression of hepatic I/R injury. The hepatocytes largely 
bear the effects of I/R injury as described in the early ischemic phase, but they also play a 
role in progression by releasing Interleukin-12 (IL-12). This interleukin may activate 
inflammatory responses, including release of the cytokines, tumor necrosis factor alpha 
(TNF-α) and Interferon gamma (IFNγ) [68]. Furthermore, hepatocytes may likely be 
responsible for the complement-driven activation of KC seen in I/R injury [69]. 
LSEC just like their hepatocyte-counterparts are largely the targets of I/R injury and similar 
to the hepatocytes in the initial phase of ischemia and ATP depletion, swell up and increase 
in volume [70]. As a result of the ensuing microcirculatory disturbance described above, 
platelets and neutrophils extravasate out into the sinusoidal spaces. The selectin family of 
adhesion molecules, P-, E- and L-selectin are expressed early during reperfusion by LSEC. 
These mediate the rolling adhesion of platelets and neutrophils that propagate the 
reperfusion injury. However, there is not much information available on the global 
physiological consequences of LSEC deregulation during hepatic I/R injury [71]. 
Parallel to hepatocyte and LSEC damage the KC are also subject to intense activation by 
damage-associated molecular patterns (DAMPs) released from the neighboring hepatocytes 
[72]. KC are also stimulated by complement and it has been reported that inhibition of the 
complement system can attenuate the severity of I/R injury. KC play a central role in the 
early phase of reperfusion and are thought to be the main source of ROS and pro-
inflammatory cytokines generated early during I/R injury [72]. The activated KC release 
TNF-α and the Interleukins -1, 6 and 12 (IL-1, IL-6 and IL-12). Although TNF-α and IL-1 
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are proinflammatory, IL-6 may have an anti-inflammatory function [72-74]. The ROS and 
inflammatory cytokines released by KC attract lymphocytes to the liver, which in their turn 
further activate cytokine secretion by the KC [75]. 
The migrating neutrophils accumulate and adhere in the sinusoidal spaces in the liver 
attracted there by selectins and trapped by the mechanical disruption of the LSEC lining 
giving direct access to the hepatocytes [71]. Here the neutrophils adhere to the intercellular 
adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) expressed on 
the hepatocytes and get primed, partly under the influence of platelets and produce ROS by 
NADPH oxidase activity. The ROS diffuse into the hepatocytes and trigger mitochondrial 
dysfunction [71, 76]. Neutrophils also release proteases and may cause hepatocyte death 
but the implication of this mechanism is unclear [77]. 
2.4.2 Reactive oxygen species (ROS) and Reactive nitrogen species (RNS) 
ROS is a term used for molecules having unpaired valence electrons or unstable bonds and 
includes radical as well as non-radical agents depending on the presence or absence of an 
unpaired electron. The most biologically significant radicals are superoxide anion (·O2
-), 
hydroxyl radical (·OH) and nitric oxide (NO) whereas the non-radical species include 
hydrogen peroxide (H2O2), singlet oxygen (
1O2), and hypochlorous acid (HOCl). 
Xanthine dehydrogenase (XDH) is an enzyme involved in purine metabolism and in 
aerobic conditions, converts the ATP metabolite, hypoxanthine to xanthine and finally to 
uric acid using NAD+ [78]. With prolonged ischemia XDH is converted to the ROS- 
forming xanthine oxidase (XO) [79]. The ATP depletion occurring due to the anaerobic 
shift as a result of ischemia, results in the accumulation of the products of its degradation 
including adenosine, hypoxanthine and xanthine. On reperfusion, initially the increase in 
oxygen delivery exceeds the rate at which cellular metabolism returns to aerobic pathways, 
which generates free radicals that damage cellular structures. Oxygen delivered to the 
ischemic tissue reacts with hypoxanthine and XO and forms superoxide and other ROS 
[80]. 
The most widely implicated ROS in hepatic I/R injury include the superoxide, hydroxyl 
radical and hydrogen peroxide [81]. These ROS are released by the KC and recruited 
neutrophils and through DNA modifications, lipid and protein peroxidation cause 
hepatocellular damage [82, 83]. ROS also increase expression of the proinflammatory 
cytokines TNF-α, IL-1β and IL-8 and are known to block mitochondrial respiratory 
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enzymes [84]. Several protective enzymes, such as superoxide dismutase (SOD) and 
glutathione peroxidase, are present in mitochondria and help to detoxify ROS [85, 86]. 
Nitric oxide (NO) and peroxynitrite (ONOO-) are the biologically most important reactive 
nitrogen species (RNS) and are produced endogenously from the amino acid L-arginine and 
oxygen by nitric oxide synthase (NOS), specifically the endothelial isoform, eNOS 
expressed in LSEC and hepatocytes [87, 88]. The inducible isoform, iNOS is upregulated in 
hepatocytes, KC and neutrophils during I/R injury and is a significant source of NO [89]. 
RNS bind to lipids, proteins and DNA and damage structural and functional components of 
the cell and the highly cytotoxic, peroxynitrite in addition inactivates several mitochondrial 
enzymes. NO produced by eNOS in the LSEC relax and dilate the sinusoids and thus 
control sinusoidal perfusion. This action is counteracted by endothelin. The eNOS isoform 
is dependent on oxygen for NO synthesis thus during hepatic ischemia there is sinusoidal 
contraction. This leads to decreased blood flow and trapping of neutrophils and platelets in 
the sinusoids [9, 90]. While it is accepted that RNS plays an important role in hepatic I/R 
injury, the exact mechanisms remain yet to be elucidated. 
2.4.3 Glucose metabolism in ischemia and reperfusion 
As described earlier, under aerobic conditions, the decarboxylation of pyruvate in the 
mitochondria yields acetyl CoA, which enters the TCA cycle [20]. Ischemia inhibits the 
further metabolism of acetyl CoA and it accumulates in the mitochondria. The accumulated 
acetyl CoA in the mitochondria is metabolized to less effective, energy substrates such as 
ketone bodies, acetoacetate and β-hydroxybutyrate [91]. The accumulation of acetyl CoA 
further inhibits pyruvate dehydrogenase leading to pyruvate accumulation in the cytosol 
which is then metabolized to lactate by the enzyme lactate dehydrogenase. This involves 
the oxidation of NADH to NAD+, and glycolysis continues. This anaerobic shift yields 2 
ATP molecules per glucose and additionally serves to keep the pyruvate concentration low. 
The result is an increase in lactate levels accompanied by a corresponding decrease in 
pyruvate levels resulting in an increased lactate/pyruvate ratio (L/Pr) [92]. While in most 
other tissues, glucose levels decrease during ischemia, in the liver, the hepatocytes respond 
to the ischemic stimulus by glycogenolysis, thereby resulting in increased intrahepatic 
glucose levels [93, 94]. This continues as long as glycogen reserves are present in the 
ischemic hepatocytes 
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2.5 REDOX REGULATORY ENZYME SYSTEMS 
The cells line of defense against ROS mediated injury includes non-enzymatic and 
enzymatic antioxidants. These include the vitamins E, A and C and enzymes like SOD and 
the H2O2 reduction agents, catalase and Peroxiredoxin [85, 86, 95]. The thioredoxin (TRX) 
and glutaredoxin (GRX) systems also play a major role in maintaining redox balance. 
These enzyme systems are expressed in all cell types [96, 97]. Many of the antioxidant 
proteins involved in ROS scavenging are regulated at the transcriptional level by binding of 
nuclear factor (erythroid-derived 2)-like 2 (NRF2), to the Antioxidant-Response Element 
(ARE) which is located upstream of the promotor of these genes and initiates the response 
against ROS [78]. NRF2 also regulates glutamate-cysteine ligase (GCLC) and 
cysteine/glutamate antiporter (xCT), which are crucial for glutathione (GSH) synthesis. 
GSH is one of the most important cellular antioxidants [98, 99]. The genes coding for xCT 
and NRF-2 are SLC7A11 and NFE2L2 respectively. 
2.5.1 The Thioredoxin (TRX) and Glutaredoxin (GRX) systems 
The TRX system consists of Thioredoxin (TXN), thioredoxin reductase (TXNRD), and 
NADPH. TXN has 2 isoforms, a cytoplasmic TXN1 and a mitochondrial TXN2 [100]. 
TXNRD also exists in cytoplasmic and mitochondrial forms, TXNRD1 and 2 respectively. 
These thioredoxins play a role in regulation of DNA synthesis and the inhibition of 
apoptosis by inhibiting enzymes involved in cell death [101, 102]. 
The GRX system includes Glutaredoxin (GLRX), GSH tripeptide (γ-glutamyl-cysteinyl-
glycine), glutathione S-reductase (GSR) and NADPH [96, 103]. The isoforms include 
GLRX1, 2, 3 and 5 differing in their localization in cytosol, nucleus and mitochondria 
[104]. The GRX systems regulate differentiation, modulation of transcription factors, and 
apoptotic pathways and like TRX plays a role in DNA synthesis [105]. The exact role and 
involvement of the TRX and GRX redox systems in hepatic I/R injury is yet unknown. 
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2.6 MICRODIALYSIS 
In both animals and humans, the effects of hepatic I/R injury have been usually studied using 
methodologies based on biopsies and blood investigations. These methods need to be 
repetitive to give a clear idea of the underlying pathophysiology and not just a momentary 
snapshot. Since its introduction in the 1950s and refinement in the following years, 
microdialysis has been developed as a tool for real-time and continuous monitoring of tissue 
metabolism, making it an ideal method to study hepatic I/R injury [106-109]. In physiological 
terms, microdialysis can be compared to repeated venous blood sampling from a specific area 
in a specific tissue to identify local metabolic events. Additionally, microdialysis avoids 
systemic dilution since it is performed directly in the tissue of interest. 
In principle, microdialysis mimics the passive function of a capillary blood vessel. A 
microdialysis catheter has a semi-permeable dialysis membrane at its tip and is introduced 
into the tissue of interest and simulates the equilibrium between capillaries and interstitial 
fluid. This equilibrium exists due to the semi-permeable nature of the capillary wall. A 
passive diffusion of small molecules occurs through this wall along the concentration 
gradient of the substance and modulated by the oncotic pressure generated by larger 
molecules incapable of passing through the wall [110, 111]. The microdialysis catheter is a 
tube with a concentric double-lumen construction and with a semi-permeable membrane 
which is composed of PolyArylEtherSulfone (PEAS) at the tip. An isotonic solution 
(perfusate) is pumped at a steady flow rate through the inner lumen, and at the tip, this 
solution comes in contact with the semi-permeable membrane. The perfusate must be isotonic 
with the fluid surrounding the tip to prevent large shifts of water across the membrane. The 
semi-permeable membrane can have a pore size or cut-off ranging from 20 to 100 kDalton 
(kDa) that can be selected based on what substance is to be measured. The perfusate at the tip 
equilibrates across the membrane with the interstitial fluid by passive diffusion and the fluid 
returning through the outer lumen of the catheter is collected in a 60 μL microvial. The 
solution collected in the microvial is called the dialysate and can then be analysed for the 
molecules in question. Figure 8 illustrates the principle of microdialysis. Glucose, lactate and 
pyruvate are commonly analysed as markers of glucose metabolism and give us information 
of the oxidative status of the tissue whereas the L/Pr is used an indicator of the redox status of 
the tissue in anaerobic states [92, 112-114]. As a marker of cell membrane injury, glycerol 
has been measured by microdialysis [112-114]. 
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Figure 8. Schematic representation of the principle of Microdialysis.  
From: Chaurasia CS, Müller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, 
Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL Jr, Lunte CE, Nordstrom CH, 
Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. AAPS-FDA 
workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res. 2007 
May;24(5):1014-25. 
Reprinted with permission from Springer Nature. 
 
 
2.6.1. Technical aspects of microdialysis 
“Recovery” reflects the dialysate concentration of the molecule being measured in relation to 
its true concentration in the tissue. The exchange of substances across the membrane and thus 
the recovery of metabolites is dependent on the rate at which the perfusate is pumped through 
the system and is also dependent on other factors including concentration gradient, molecular 
size, membrane surface area and pore size, temperature and probably other factors not well 
understood yet. Thus, standardization of the technique is essential for accurate results. A 
reliable pump system is a prerequisite and the perfusate injector needs to maintain a steady 
flow rate. A high flow rate can force fluid out into the interstitium and thus results in a lower 
recovery. Perfusion rates of 0.3, 0.5, 1, 2 and 5 μl/minute have been used with slower 
 20 
velocities used to achieve highest possible recovery [115, 116]. As mentioned earlier the 
membrane pore size is selected depending of the metabolite being studied and molecules 
smaller than the pore size diffuse through. However, larger molecules even with a smaller 
size than the pores have a lower velocity and diffuse less easily across the membrane [117, 
118]. To achieve high recovery, a long membrane with the right pore size and a low perfusion 
rate is needed. Temperature also influences the diffusion rate and recovery increases by up to 
1-2% per degree Celsius increase in temperature [119, 120]. 
When the microdialysis catheter is introduced into a tissue, there is trauma to the tissue with 
an ensuing inflammatory response. This response ‘normalizes by around 30-60 minutes and 
is the time needed for equilibration. This duration has been shown to vary depending on the 
metabolite being analyzed and longer equilibration times have been reported [121-123].  
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3 AIMS 
 
The general aim of the thesis was to increase the understanding of the phenomenon of hepatic 
I/R injury at a metabolic and cellular level. Furthermore, we aimed to investigate the use of 
monitoring methods like microdialysis in both clinical and experimental settings of hepatic 
I/R injury.  
The specific aims of this thesis were: 
1. To study the metabolic effects of portal triad clamping in human subjects undergoing liver 
resection using microdialysis as a monitoring tool. 
2. To study whether microdialysis catheters with a cut-off of 20 and 100 kDa can be used 
equally in the measurement of the small molecules, glucose, glycerol, lactate and pyruvate in 
a pig liver model. 
3. To investigate whether intravascular microdialysis using a catheter placed by a transjugular 
approach in the middle hepatic vein is comparable to direct intrahepatic microdialysis for 
metabolic monitoring of arterial ischemia in a pig liver model. 
4. To investigate the effect of warm I/R injury induced by PTC on hepatic cellular 
ultrastructure and on the expression of the thioredoxin (TRX) and glutaredoxin (GRX) 
systems in human subjects. 
5. To evaluate whether monitoring the L/Pr ratio by intrahepatic microdialysis can be used 
clinically as a marker for the detection of ischemic complications early after LT. 
6. To study if monitoring of glucose, lactate, pyruvate and glycerol by intrahepatic 
microdialysis can be used clinically to predict ACR early after LT. 
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4 METHODS 
4.1 PAPER I 
4.1.1 Study design and patients 
This study was a feasibility study to establish the technique of microdialysis in human 
subjects undergoing liver resection and to characterize changes associated with warm 
ischemia induced by PTC. Eleven consecutive patients undergoing liver resection were 
included in the study and a prerequisite was that none had clinical or biochemical signs of 
chronic liver disease. Ten of these patients had metastases of colorectal cancer of which 
seven had received chemotherapy prior to surgery. 
4.1.2 Study protocol and microdialysis 
After laparotomy, the microdialysis catheter was inserted into segment IV of the liver using a 
plastic guider and steel cannula, taking special care not to penetrate tumor tissue. The CMA 
70 microdialysis catheter, 0.9mm with a membrane cut-off of 20 kDa (CMA Microdialysis 
AB, Stockholm, Sweden) was inserted and a 5-0-prolene suture used to secure the catheter 
and fix it to the falciform ligament. The catheter was then connected to a syringe with 
perfusion fluid, which was a Ringer acetate-like solution, T1 (CMA Microdialysis AB) and 
then placed in a microinfusion pump. A flow rate of 1 μl/minute was set after which 30-60 
minutes of perfusion was required for equilibration. PTC was then performed using a 
standard technique where a soft cloth tape was passed around the porta hepatis over which a 
rubber tubing was then slid. Using a hemostat, the rubber tubing was used to constrict the 
vessels in the hepatoduodenal ligament. Microvials were changed every 10 minutes and 
sampling was continued during equilibration, 20 minutes of portal triad clamping, and 10 
minutes after reperfusion. The liver was not manipulated, and infusions of glucose and 
vasopressor drugs were withheld during the experimental period. 
4.1.3 Statistical analysis 
Statistical analyses were performed using Statistica 8.0 software. The data were presented as 
mean ± SE and comparison of more than two means were performed using Friedman 
ANOVA with Wilcoxon matched pair test. Correlations between microdialysis and reference 
variables were done using linear regression analyses. Tests with p values <0.05 were 
considered statistically significant. 
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4.2 PAPER II 
4.2.1 Animals and anaesthesia  
A total of six female pigs approximately 30-35 kg in weight were used in the study. All 
animals were fasted for 24 hours with free access to water prior to the experiments. After 
premedication, midazolam was administered intravenously and the animal intubated. 
Anaesthesia was maintained by halothane and complemented with fentanyl. Ringer acetate 
was infused intravenously at 37°C. Blood gas analysis, electrocardiogram, body temperature 
and urine production were monitored throughout the experiment. Body temperature was 
maintained at 38°C to 39°C. 
4.2.2 Surgical procedure and microdialysis study protocol 
A midline laparotomy was performed, and four microdialysis catheters were inserted into 
different segments of the liver of each pig using a steel cannula with a split catheter and then 
sutured to the liver parenchyma using a method described earlier [92]. Two of the catheters 
had the membrane cut-off of 20 kDa and two of 100 kDa (CMA 70 and CMA 71). After 
insertion the inlet of the tubings was connected to the CMA 106 microinfusion pump and 
perfusion started. Ringer acetate-like perfusion fluid T1 was pumped through the 20-kDa 
catheters (referred to as 20R and 20R1) and one of the 100-kDa catheters (100R) at a flow 
rate of 0.3 μl/minute. The other 100 kDa was pumped with hydroxyethyl starch (100V) 
(Voluven, Fresenius Kabi, Sweden) at the same flow rate. Equilibration was carried out for 
60 minutes after catheter implantation and before the start of collection of dialysate samples. 
Microdialysate samples were collected at 40-minute intervals. The duration of the experiment 
was 240 minutes. The liver was not manipulated during the experimental period. The samples 
were analyzed using colorimetric methods with a CMA 600 microdialysis analyzer for 
glucose, glycerol, lactate and pyruvate using enzymatic reagents and colorimetric 
measurements.  
4.2.3 Statistical analysis 
Statistical analyses were performed using Statistica 8.0 software. Data were presented as 
mean ± SEM and coefficients of variation (CV) for dialysate concentrations of the given 
molecules in the different catheters. Data were analyzed using ANOVA with Scheffe’s post 
hoc test and tests with p values <0.05 were considered statistically significant. 
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4.3 PAPER III 
4.3.1 Animals and anaesthesia  
A total of eight female littermate pigs, with a body weight of 30-35 kg, were used for the 
experiments. Before the operation, all animals were fasted for 24 hours with free access to 
water. The anaesthesia procedure was identical to study II.  
4.3.2 Surgical procedure and microdialysis study protocol 
Before the abdominal part of the experiment, a CMA 60 microdialysis catheter with a 20-mm 
shaft and a 30-mm membrane was inserted just under the skin over the left pectoral area as a 
subcutaneous reference catheter. A midline laparotomy was then performed and the 
intrahepatic microdialysis catheter was inserted into the middle lobe of the liver using a 
similar method as used for study II. The CMA 70 microdialysis catheter with a 60-mm shaft 
and a 30-mm membrane was used in the liver. In the next step the right internal jugular vein 
was isolated and the 67 IV microdialysis catheter (M Dialysis AB) with a 130-mm shaft and a 
30-mm membrane was introduced into it.  The tip of the catheter was placed in the middle 
hepatic vein and advanced till it stopped in the liver. Then, the inlets of the tubings were 
connected to microinfusion pumps (CMA 106) and perfusion started using T1 solution at a 
flow rate of 0.3 µl/min in the intrahepatic and subcutaneous catheters and 1 µl/minute in the 
hepatic vein catheter. A 2-hour period was needed for equilibration and a steady state was 
achieved after one hour of catheter placement.  The hepatic arteries were dissected, isolated, 
ligated and divided one hour later. This “clamping” was carried on for a period of four hours. 
Dialysate samples were collected at 15-minute intervals from the intrahepatic and intravenous 
catheters and at 30-minute intervals from the subcutaneous catheter during the experimental 
period. The liver was not manipulated during the monitoring period. Dialysates were 
analyzed for glucose, glycerol, lactate and pyruvate and the lactate/pyruvate ratio (L/Pr) was 
calculated. The samples were analyzed using colorimetric methods with a CMA 600 
microdialysis analyzer. At the end of the experiment the pigs were sacrificed by an overdose 
of anaesthesia.  
4.3.3 Statistical analysis 
Statistical analyses were performed using Statistica 13.2 software program. Data were 
presented as mean ± 95% confidence intervals (CI) for each metabolite (Glucose, Lactate, 
Pyruvate, Glycerol and the L/Pr) and for each catheter (Intrahepatic, Hepatic vein and 
Subcutaneous). Results were compared using ANOVA for repeated measurements. In case of 
  25 
significant differences, analyses were complemented with the Bonferroni post-hoc test. Tests 
with p values <0.05 were considered statistically significant. 
 
4.4 PAPER IV 
4.4.1 Study design and patients 
Eleven patients undergoing liver resection for differing indications were included in the 
study. Seven of these patients had colorectal liver metastases and had received preoperative 
chemotherapy. None of the patients had clinical or biochemical signs of chronic liver disease,  
4.4.2 Study protocol and biopsy acquisition 
After laparotomy and division of the falciform ligament, the hepatoduodenal ligament was 
isolated, and a PTC then performed as described for study I for a period of 20 minutes. 
Biopsies (one wedge and two needle) were taken at three time-points; baseline (just before 
the application of PTC), post-ischemia (after 20 minutes of PTC) and post-reperfusion (after 
20 minutes of reperfusion). The needle biopsies were immediately transferred to the buffers 
and then stored at 4℃ for further analyses. The wedge biopsies were transferred to vials that 
were immediately frozen in liquid nitrogen and stored at -70℃ until analysis. The liver was 
not manipulated during the experimental period. The liver resection then proceeded as 
planned. 
4.4.3 Transmission electron microscopy  
The needle biopsies were fixed, washed and dehydrated with appropriate reagents and 
according to standard protocol. The embedded biopsies were sectioned using an 
ultramicrotome (Leica EM UC 6). A transmission electron microscope (Tecnai 12 Spirit Bio 
TWIN) was used to examination the sections and a Veleta® camera used for capturing digital 
images. The EM images were evaluated for cellular architecture, hepatocyte morphology, 
sinusoids and bile canaliculi. 
4.4.4 Morphometric image analysis 
Quantification analysis of the sinusoids in the EM images was performed using NIS Elements 
Basic Research software. Pixel length measurements were applied on the sinusoidal 
endothelial lining and the number of pixels was determined on one representative sinusoid for 
each patient and time point. The length of the endothelial lining was correlated to the length 
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of the entire sinusoid and the retrieved pixel value was related to actual μm for comparison 
between different images. 
4.4.5 Immunoelectron microscopy 
Needle biopsies were prepared and sectioned and primary antibodies of TRX1 and GRX1 
were applied on the sections overnight in a humidified chamber at room temperature [124]. 
The sections were prepared further including rinse with gold at a dilution of 1:100. Then a 
transmission electron microscope (Tecnai G2 Bio TWIN) was used for examination and 
images captured by the Veleta® camera. Quantification of the staining was performed on five 
hepatocytes in close proximity to vessels for each tissue section. The number of gold particles 
in the cytosol and the nuclei were documented. 
4.4.6 RNA purification, cDNA synthesis and qPCR 
The fresh frozen wedge biopsies were processed according to standard protocol and RNA 
purification carried out. Assessment of RNA quality revealed that 6 out of 11 patients had 
good quality of samples from all time points. For cDNA synthesis, 2 μg RNA was subjected 
to reverse transcription and then subjected to qPCR. The genes of interest were isoforms of 
thioredoxins (TXN) and glutaredoxins (GLRX) and the gene of xCT and NRF-2, SLC7A11 
and NFE2L2 respectively.  
4.4.7 Statistical analysis 
The statistical analysis was performed using GraphPad Prism 6.0 software. The non-
parametric Friedman test followed by Dunn’s post-hoc test was used for the analysis of 
endothelial lining, gene expression data, and immunogold staining data. Tests with p values 
<0.05 were considered to be statistically significant. 
 
4.5 PAPER V 
4.5.1 Patients, transplant procedure and postoperative blood glucose management 
Forty-five patients undergoing LT for various indications at the Karolinska University 
Hospital, Stockholm, Sweden, were included prospectively in the study. The piggyback 
technique was the standard and in selected cases veno-venous bypass was used. Steroids and 
Tacrolimus were used as basic immunosuppression and high molecular weight Dextran for 
thrombosis prophylaxis. Ultrasound was the clinical routine to evaluate the liver circulation 
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within 24 hours after LT. Postoperatively blood glucose was measured every hour by arterial 
blood gas and patients were administered 5% glucose infusions at 30 ml/kg/day on day 1 and 
2. Total parenteral nutrition and a full diet were successively introduced. Initially a target 
blood glucose value of 4–8 mmol/L was achieved with insulin.  
4.5.2 Microdialysis and study protocol 
At the end of surgery, but before abdominal closure, the CMA 61 microdialysis catheter with 
a 60 mm shaft (0.9 mm diameter), a 30 mm membrane (0.6 mm diameter) and a molecular 
cut-off of 20 kDa was inserted into segment IV of the liver graft. Another CMA 60 catheter 
reflecting systemic changes was placed subcutaneously in the right pectoral area as a 
reference catheter. Perfusion fluid T1 was perfused using CMA 106 microinfusion pumps at a 
flow rate of 0.3 μl/minute. Dialysate samples were collected once every hour and patients 
were monitored for up to six days postoperatively. Analyses were performed in the CMA 600 
Microdialysis Analyzer and dialysates were analyzed for glucose, lactate, and pyruvate 
concentrations, and the L/Pr was calculated for both catheters. An ischemic complication was 
defined as vascular occlusion or graft infarction confirmed by radiology. Clinical or 
laboratory suspicion of such vascular complications, including raised L/Pr beyond cut-offs 
decided in the protocol were investigated by contrast ultrasound of the liver and a 4-phase 
liver CT scan if needed. According to the protocol an episode with three consecutive samples 
with increasing L/Pr where the increase was at least 30% in total was considered for further 
investigation. The 30% cut-off was based on our earlier studies and assuming that this level 
would be clinically relevant [92, 125]. 
4.5.3 Statistical analysis 
Statistical analysis was performed using the Statistica 13.2 software. Episodes with increased 
intrahepatic L/Pr above the cut-off decided in the protocol were identified. The clinical 
outcome was compared for patients with and without such episodes. Episodes with systemic 
glucose increase (defined as three consecutive samples with increasing glucose and a 
minimum increase of 30% in total) measured in the reference catheter were identified. These 
episodes were studied for correlation in time to intrahepatic L/Pr increase. Also, the data were 
analyzed with respect to cut-off values for lactate and L/Pr at 3 mmol/L and 20, respectively, 
based on the study by Haugaa et al. [126]. Data were presented as mean ± SE.  
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4.6 PAPER VI 
4.6.1 Patients, transplant procedure and postoperative management 
Seventy-one consecutive patients undergoing LT at the Karolinska University Hospital, 
Stockholm for differing indications were included in the study. Aspects of LT were as 
described for study V (see before). A “time-zero biopsy” was obtained from the graft after 
complete revascularization. Blood work including transaminases, bilirubin and PT-INR were 
collected according to the standard clinical routine postoperatively. ACR within one month 
was diagnosed by either a sudden and marked increase in transaminases only or by increased 
transaminase levels confirmed by liver biopsy. 
4.6.2 Microdialysis and study protocol 
Intrahepatic microdialysis using the CMA 61 catheter was performed in a similar fashion as 
described in study V. Samples were collected at 1-hour intervals for up to six days post-
operatively. Dialysates were analyzed with respect to glucose, glycerol, lactate and pyruvate 
concentrations and the L/Pr was calculated. Time-zero biopsies were graded for I/R injury 
using the modified Suzuki score [127]. 
4.6.3 Statistical analysis 
Statistical analyses were performed using Statistica 13.2 software and SPSS 25 program. All 
patients with more than 24 hours of microdialysis data were included in the analyses. Patients 
were divided into 2 groups, those who experienced rejection and those without. Area under 
the curve (AUC) was calculated for 12-hour intervals for glucose, lactate, pyruvate, glycerol 
and the L/Pr for all patients. The two groups were compared with respect to these parameters, 
standard blood work (transaminases, bilirubin, PT-INR) and the “time-zero”- biopsy using 
ANOVA, t-tests and U Mann-Whitney or Kruskal-Wallis’ test for nonparametric or non-
normal distributed data as appropriate. A forward stepwise logistic regression analysis was 
performed to determine whether the changes detected were predictive for rejection or not. 
Data were presented as mean ± standard error and mean ± 95% CI where appropriate. The 
level of statistical significance for each test was set at p<0.05. 
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4.7 Ethics 
Human studies (Studies I, IV, V and VI): The study protocols of all the human studies 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved 
by the Ethics Committee for Human Studies at the Karolinska Institute and by the Regional 
Ethics Committee for Human Studies, Stockholm, Sweden. Informed and written consent 
was obtained from all patients participating in the studies. 
Animal studies (Study II and III): The animal studies were approved by the Regional 
Ethics Committee for Animal Experimentation, Stockholm, Sweden. All animals involved in 
the experiments received care in accordance with Swedish regulations. 
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5 RESULTS 
5.1 PAPER I 
There were no intra- or post-operative complications attributable to the microdialysis 
procedure. During PTC, there were significant increases in intrahepatic glucose, lactate, and 
glycerol levels. Levels increased from 9.1 ± 2.2 to 14.5 ± 2.4mM, from 2.2 ± 0.3 to 5.8 ± 
0.5mM, and from 63 ± 14 to 142 ± 28 µM, for glucose, lactate and glycerol respectively 
(p=0.007, 0.008 and 0.012 respectively). Pyruvate levels during PTC however remained 
unchanged, resulting in an increased L/Pr from 39 ± 10 to 104 ± 32 (p=0.012). During 
reperfusion, glucose and pyruvate increased, while lactate remained stable, resulting in the 
normalization of the L/Pr (p=0.012). Glycerol continued to increase to 163 ± 42 µM during 
initial reperfusion. 
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Figure 9. Glucose, lactate, pyruvate, glycerol levels and L/Pr measured by intrahepatic 
microdialysis before, during 20 minutes of PTC and after 10 minutes of reperfusion.  
 
5.2 PAPER II 
The average glucose concentrations measured by the catheters 20R, 20R1, 100R and 100V 
were 5.8 ± 0.5, 6.9 ± 0.7 mM, 7.0 ± 0.8 and 6.5 ± 0.7 mM (CVs 0.58, 0.65, 0.72 and 0.64), 
respectively, thus comparable and showing no difference.  
Similarly, glycerol levels measured showed no significant difference between the four 
catheters. Levels measured by 20R, 20R1, 100R and 100V catheters were 10.9 ± 1.2, 9.9 ± 
1.9, 13.6 ± 2.0 and 9.7 ± 2.0 µM (CVs 0.70, 1.19, 0.93 and 1.12) respectively.  
Dialysate lactate concentrations measured by the 20R, 20R1, 100R and 100V catheters were 
2.5 ± 0.1, 2.4 ± 0.1, 3.1 ± 0.2 and 2.7 ± 0.2 mM (CVs 0.44, 0.48, 0.42 and 0.46), respectively, 
showing no significant differences.  
Dialysate concentrations of pyruvate measured by the 20R, 20R1, 100R and 100V catheters 
were 107.0 ± 7.6, 86.0 ± 7.3 µM), 128.1 ± 6.4 and 115.6 ± 8.2 µM (CVs 0.44, 0.52, 0.30 and 
0.43) respectively. Pyruvate measurements by the 100R catheter were higher as compared to 
the 20R1 catheter (p<0·01).  
The L/Pr for the catheters 20R, 20R1, 100R and 100V showed no difference and were 25.7 ± 
1.6, 24.8 ± 1.2, 29.6 ± 1.5 and 24.2 ± 0.8 (CVs 0.38, 0.30, 0.32 and 0.22) respectively. 
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Figure 10. Mean (± SEM in whiskers) dialysate concentrations for glucose, glycerol, 
lactate, pyruvate and the calculated L/Pr for the catheters 20R, 100R, 100V and 20R1. 
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5.3 PAPER III 
Glucose and glycerol levels measured by the three catheters showed no differences over the 
course of the experiment before and after arterial clamping. 
After arterial clamping, between 60-120 minutes in the subcutaneous catheter and between 
105-150 minutes in the intrahepatic catheter lactate levels were significantly higher as 
compared to before clamping. These differences were significant (p<0.01). 
There were significant differences between pyruvate measured by the three catheters 
(p<0.001).  Pyruvate levels increased subcutaneously between 60-120 minutes after arterial 
clamping (p<0.01) and decreased as measured in the intrahepatic catheters from 90 minutes 
onwards after clamping (p<0.001).  
L/Pr measured by the three catheters throughout the experiment showed no differences. 
 
 
 
 34 
 
Figure 11. Glucose, glycerol, lactate and pyruvate levels and L/Pr (mean±95% CI) 
measured in the liver, hepatic vein and subcutaneous catheters before and after arterial 
clamping. Lactate and pyruvate levels showed significant differences. 
 
5.4 PAPER IV 
5.4.1 Hepatic ultrastructure and morphometry 
On EM examination at baseline, the biopsies showed normal hepatocyte and LSEC 
morphology. The hepatocytes had large numbers of mitochondria. The hepatocytes in the 
space of Disse showed intact microvilli extensions and normal fenestrated LSECs lined the 
sinusoids.  
Post-ischemia the most prominent finding was a disruption of the LSEC lining in 10 out of 11 
patients. The hepatocyte microvilli decreased in number and were undetectable in some 
cases. Apart from this the hepatocytes had a remarkably preserved morphology with intact 
membranes. The hepatocyte mitochondria were dilated and exhibited aggregates, so-called 
“crystalline inclusions” post-ischemia seen in 7 of 11 patients.  
Post-reperfusion, there was an apparent reactivation of the LSECs with pseudopod-like 
extensions appearing from the LSEC surface. In some sections LSEC apoptosis and 
phagocytosis by KC was noticed. The hepatocyte morphology remained normal and 
microvilli returned to their normal state. The mitochondrial crystalline inclusions persisted. 
These findings are shown in Figures 12 and 13 and quantified in Table 1. 
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Figure 12. EM images at baseline, post-ischemia and post-reperfusion showing the 
salient findings. LSEC disruption, and loss of hepatocyte microvilli are seen post-
ischemia and LSEC reactivation post-reperfusion. 
 
Figure 13. Crystalline mitochondrial inclusion and a few dilated mitochondria seen 
post-ischemia in the hepatocyte. 
Table 1. Quantitative summary of ultrastructural changes. N observations/11 patients 
 Baseline Post-ischemia Post-reperfusion 
Disruption of endothelium 2/11 10/11 2/11 
Endothelial activation 4/11 3/11 9/11 
Mitochondrial inclusions in hepatocytes 1/11 6/11 7/11 
Lipids, lipofucsin 10/11 10/11 10/11 
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Morphometric image analysis to evaluate the loss and reactivation of the LSEC lining was 
expressed as a percentage of intact LSEC lining of the total length of the hepatic sinusoid. 
This revealed a quantitatively significant reduction in the lining post-ischemia compared to 
baseline (p=0.0003). There was no difference between the baseline level and the post-
reperfusion, indicating LSEC lining recovery (Figure 14). 
 
Figure 14. Morphometric analysis showing reduction in LSEC lining post-ischemia. 
 
5.4.2 Immunoelectron microscopy 
 
Figure 15. Quantification of immunogold staining. Number of gold particles of 5 
hepatocytes for each time point and patient. A - C for TRX and D - F for GRX.               
A and D – Cytosol, B and E – Nuclei, C and F – Cytosol and nuclei 
Immunogold staining for GRX1 and TRX1 showed no significant changes in the amount of 
TRX1 in the hepatocyte nuclei or cytosol during I/R injury. The total amount of TRX differed 
in the hepatocytes between the time points. During ischemia TRX level decreased in five, 
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remained unaffected in three, and increased in two patients (Table 2) while GRX1 levels did 
not change in any of the patients (Figure 15). 
Table 2. Levels of TRX1, evaluated by immunogold staining, total number of gold 
particles present in five hepatocytes 
Patient Baseline Post-ischemia Post-reperfusion 
P1 794 357 414 
P2 310 202 323 
P3 1217 235 219 
P4 373 176 298 
P5 324 231 232 
P6 269 273 443 
P7 575 569 252 
P8 294 221 699 
P9 535 863 417 
P10 590 755 272 
 
5.4.3 Gene expression analysis of redox regulating systems 
Relative mRNA expression of NFE2L2 and SLC7A11, coding for the redox regulatory 
proteins NRF-2 and xCT, were investigated along with the TRX family of proteins. There 
were no differences post-ischemia or post-reperfusion compared with baseline (Table 3). 
 
Table 3. Gene expression of redox proteins changes in mRNA expression compared to 
baseline, calculated using the 2-ΔΔCT method 
 
TNX1 TNX2 TNXR1 TNXR2 GLRX1 GLRX2 GLRX3 GLRX5 NFE2L2 SLC7A11 
Ischemia 1.09±0.18 1.14±0.30 1.02 ± 0.28 1.05 ± 0.23 1.19 ± 0.41 1.24 ± 0.46 1.03 ± 0.16 1.20 ± 0.27 0.83 ± 0.15 1.27 ± 1.24 
Reperfusion 1.12±0.25 1.31±0.57 0.97 ± 0.33 1.39 ± 0.79 1.12 ± 0.67 1.16 ± 0.43 1.16 ± 0.26 1.18 ± 0.63 1.00 ± 0.44 1.22 ± 0.78 
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5.5 PAPER V 
5.5.1 Illustrative Case reports 
Patient 1  
A young male recipient underwent LT and 22 hours after LT the intrahepatic L/Pr, measured 
by microdialysis, increased by 70% over a period of two hours, reaching a level of 17.6. 
Lactate remained stable at around 1.2 mM and pyruvate levels decreased during this L/Pr 
increase. L/Pr soon returned to previous levels even though pyruvate and lactate levels 
continued to rise. On day 10, HAT was diagnosed and the patient reoperated and a 
thrombectomy performed. Unfortunately, the patient eventually developed cholestatic liver 
failure and had to be retransplanted. It is likely that HAT occurred during the episode with 
raised L/Pr but the rise was expected to be higher and more prolonged and did not result in 
any further radiologic investigation at the time. 
 
A                     B 
Figure 16. Intrahepatic L/Pr and systemic glucose (A) and intrahepatic lactate and 
pyruvate levels (B) measured by microdialysis for patient case report 1. 
Patient 2  
A middle-aged male underwent LT and 65 hours after LT, a 50 % increase in the L/Pr was 
seen over a 3-hour period, reaching a level of 10.8. HAT or PVT was suspected, and an 
ultrasound followed by a CT angiography was performed showing normal liver circulation. 
The patient had an uneventful postoperative course thereafter. Analysis showed that during 
the L/Pr rise pyruvate levels decreased while lactate levels remained stable. Also, the patient 
experienced an increase in systemic glucose 3 hours after the episode of elevated L/Pr due to 
a stop in the intravenous insulin infusion.  
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A                                                                                   B 
Figure 17. Intrahepatic L/Pr and systemic glucose (A) and intrahepatic lactate and 
pyruvate levels (B) measured by microdialysis for patient case report 2. 
5.5.2 Overall results 
No complications related to the microdialysis procedure were observed. Liver graft cold 
ischemia time ranged from 322-960 minutes (median=718 minutes). 
Intrahepatic glucose, lactate, pyruvate and the L/Pr levels in the entire cohort are shown in 
Figure 18. There was no time correlation between episodes of increased L/Pr and episodes of 
increase in systemic glucose and no correlation was between intrahepatic glucose and lactate. 
 
A                                                                                    B 
Figure 18. Intrahepatic L/Pr and pyruvate (A) and glucose and lactate (B) levels 
following LT for the entire cohort. Data presented as mean ± SE. 
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One patient of 45 in the cohort developed HAT (case report 1). The data revealed 44 events 
of increased L/Pr (as per study protocol) in 24 patients, none had any clinical, biochemical or 
radiological signs of ischemic complications. Further analysis of these episodes showed that 
in 26 of 44 cases the increase was with decreasing lactate and pyruvate levels. In 10 cases 
there was an increase in lactate and pyruvate levels and in 8 cases the increase in L/Pr was 
associated with an increase in lactate and decrease in pyruvate. Eight patients (17%) had at 
least one L/Pr value above the cut-off of 20 and a lactate value above the cut-off of 3mM but 
without any ischemic complications [126]. L/Pr and lactate values in the patient with HAT 
did not reach the protocol suggested cut-off values. The results are summarized in Tables 4 
and 5. 
Table 4. Metabolic events and ischemic complications 
 1 patient with ischemic 
complication* 
44 patients without ischemic 
complications 
Events of increase in L/Pr 0 44 (in 24 patients) 
Events of increase in systemic glucose  0 116 (in 39 patients) 
Events of increase in systemic glucose with 
simultaneous increase in L/Pr 
0 15 
Number of simultaneous L/Pr and lactate values 
above cut-off 
0 8 
 
 
Table 5. Analysis of lactate and pyruvate levels in relation to increased L/Pr 
 Lactate ↑ Lactate ↓ 
Pyruvate ↑ n = 10 (23%) n = 0 (0%) 
Pyruvate ↓ n = 8 (18%) n = 26 (59%) 
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5.6 PAPER VI 
There were no major adverse events related to the microdialysis procedure. Mean ischemia 
time was 563 minutes for patients who experienced rejection and 561 for those who did not. 
Of the 71 patients in the study, 33 (46%) developed ACR within the first month post-LT and 
was detected on an average 11 days (range 5-23) after transplantation. There was no 
difference between the groups regarding donor related parameters such as age, cold ischemia 
time and time-zero biopsy pathology or liver blood chemistry (Tables 6 and 7). However, 
ASAT was higher in patients with rejection group on day 7 post-LT. 
 
Table 6. Donor age, ischemia time and time-zero biopsy evaluation. 
 
 Mean (Non-
rejection) 
Mean 
(Rejection) 
Standard 
Error (Non-
rejection) 
Standard 
Error 
(Rejection) 
p-value 
Donor age (years) 47.4 53.8 3.1 2.7 0.09 
Ischemia time (min) 561 563 28.7 29.2 0.9 
Graft steatosis1 1.2 1.3 0.07 0.1 0.4 
Graft ischemia2 2.0 1.8 0.1 0.1 0.2 
 
 
1 Graft steatosis was graded on a scale of 1-3; 1 = <10% steatosis / 2 = 11-20% steatosis / 3 = 20-30% 
steatosis 
2 Graft ischemia was graded on a scale of 1-3; 1 mild ischemia / 2 moderate ischemia / 3 severe ischemia 
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Table 7. Standard liver blood tests during the first week post-transplantation. 
 
Data presented as mean±SEM for patients without vs. with rejection. Significant differences between 
groups are highlighted * (p<0.05). 
 
In the cohort only three patients remained with microdialysis monitoring up to day 6 or 
longer while the majority had the catheter removed around day 3. Only the first 72 hours of 
data was available for all patients and microdialysis results are presented in Figure 19. 
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ALAT (µkat/L) 
 
 
 
ASAT (µkat/L) 
 
 
 
Bilirubin (µmol/L) 
 
 
 
PT-INR 
 
 
Non-rejection 
 
Rejection 
 
Non-rejection 
 
Rejection 
 
Non-rejection 
 
Rejection 
 
Non-rejection 
 
Rejection 
 
Day 1 
 
18.81±2.68 
 
21.01±2.82 
 
23.30±3.58 
 
30.50±5.13 
 
53.56±6.21 
 
56.33±10.21 
 
1.75±0.05 
 
1.68±0.07 
 
Day 2 
 
17.35±2.33 
 
21.17±3.50 
 
15.30±2.10 
 
22.86±5.49 
 
46.28±5.78 
 
47.33±6.40 
 
1.58±0.07 
 
1.53±0.07 
 
Day 3 
 
14.58±2.09 
 
17.16±2.51 
 
9.63±1.44 
 
13.05±2.21 
 
54.90±7.39 
 
80.01±35.54 
 
1.43±0.05 
 
1.36±0.04 
 
Day 4 
 
10.32±1.45 
 
12.49±1.63 
 
4.81±0.58 
 
6.95±0.99 
 
71.77±9.10 
 
50.78±5.08 
 
1.32±0.03 
 
1.30±0.03 
 
Day 5 
 
7.27±0.99 
 
8.88±1.08 
 
2.56±0.27 
 
3.71±0.50 
 
77.80±10.0 
 
54.87±5.60 
 
1.31±0.04 
 
1.27±0.03 
 
Day 6 
 
5.11±0.62 
 
6.75±0.72 
 
1.59±0.16 
 
2.30±0.22 
 
73.54±9.96 
 
64.60±6.20 
 
1.31±0.03 
 
1.30±0.03 
 
Day 7 
 
4.07±0.46 
 
5.53±0.57 
 
1.13±0.12 
 
1.75±0.22* 
 
75.59±9.86 
 
66.43±8.45 
 
1.28±0.03 
 
1.29±0.04 
  43 
Figure 3.
0-12 12-24 24-36 36-48 48-60 60-72
Time intervals in hours.
1600
1800
2000
2200
2400
2600
2800
3000
3200
3400
3600
3800
4000
4200
A
U
C
 p
y
ru
v
a
te
 Non-rejection
 Rejection
Figure 4.
0-12 12-24 24-36 36-48 48-60 60-72
Time intervals in hours.
80
100
120
140
160
180
200
220
240
260
280
300
A
U
C
 L
a
c
ta
te
/p
y
ru
v
a
te
 r
a
ti
o
 Non-rejection
 Rejection
 
C                                                    D 
Figure 19. AUC values for glucose, lactate, pyruvate and L/Pr (A-D) for patients with 
and without rejection. Data presented as mean ± 95% confidence intervals. 
The L/Pr was higher in the group with rejection at 1-12 hours after LT. Glucose was higher in 
the group without rejection at 24-48 hours. Lactate levels were higher at 48-72 hours and 
pyruvate levels were higher at 60-72 hours post-LT in the rejection group as compared to the 
non-rejection group. Glycerol levels showed no difference between the groups.  
The forward stepwise logistic regression model showed that only L/Pr during the first 12 
hours post-LT was an independent predictor of early post-transplant rejection (p=0.05).  
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6 DISCUSSION 
6.1 PAPER I 
At the time of publication, this study was one of the first to investigate microdialysis in 
human non-transplanted livers. The aim was to establish the feasibility of intraoperative 
microdialysis in liver resection patients and to study the effects of warm ischemia induced by 
PTC. We could show that microdialysis could be safely performed in these patients without 
any procedure-related complications. 
The results of the study revealed substantial metabolic alterations associated with PTC with 
increasing glucose, lactate and glycerol levels measured by intrahepatic microdialysis. 
Pyruvate levels were stable and the L/Pr thus rose significantly. These findings were 
consistent with previously published animal studies on warm ischemia [92, 112]. The 
increase in glucose levels could be attributed to hypoxia induced glycogenolysis and possibly 
gluconeogenesis [128]. On reperfusion glucose levels continued to rise due to the 
reestablishment of the blood supply. Due to the shift to anaerobic metabolism as a result of 
PTC, ATP production is sustained by the reduction of pyruvate to lactate and the resulting 
raised L/Pr is a better indicator of ischemia than just the raised lactate alone [92, 129, 130]. 
Pyruvate levels did not decrease during PTC-induced warm ischemia but remained stable and 
could be due to the increased glucose levels, similar to previous reports [112, 114]. Pyruvate 
levels increased significantly on return to aerobic conditions during reperfusion and lactate 
levels remained stable during the initial phases reflecting a post-ischemic hypermetabolism. 
Glycerol is a key constituent of the cell membrane. Damage to the cell wall as a result of 
ischemia causes glycerol to leak out into the interstitium, which can then be measured by 
microdialysis as a marker of cell membrane damage [112-114, 131, 132]. In our study 
glycerol levels rose during PTC and during reperfusion suggesting a persistent cell membrane 
damage probably a result of the free radical mediated damage to cellular structures caused by 
reperfusion injury [60].  
This study showed that at the metabolic level there were significant changes induced by PTC- 
associated warm I/R injury and these could be measured by intrahepatic microdialysis. The 
findings of the study documented the deviations in glucose metabolism and the cell 
membrane damage occurring as a result of this injury. PTC or the Pringle manoeuvre has 
been proven to be an effective method to reduce blood loss during liver surgery and is 
sometimes an indispensable surgical tool but is still used selectively [44, 45]. The results of 
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our study suggest that in situations with compromised liver function the hepatic parenchymal 
injury induced by PTC must be taken into consideration when deciding on its use and 
duration. 
 
6.2 PAPER II 
Hepatic microdialysis is conventionally performed using catheters with a membrane cut-off 
of 20-kDa to measure the small metabolites glucose, lactate, pyruvate and glycerol. Larger 
molecules like cytokines, chemokines and complement play a significant role in I/R injury 
and studying these molecules entails the use of microdialysis catheters with a larger cut-off of 
100 kDa [133, 134]. The aim of this study was to evaluate whether 100-kDa catheters could 
be used to measure small molecules such as glucose, lactate, pyruvate and glycerol with 
equivalent results as 20-kDa catheters in a pig liver model. 
The study design was to use two catheters with 20 kDa cut-off and two with a 100 kDa cut-
off. To circumvent the issue of volume loss when using 100-kDa catheters we used the 
colloid solution Voluven (hydroxyethyl starch) as perfusion fluid for one of the 100-kDa 
catheters in our study. In doing so, the aim was to counteract the osmotic effect of plasma 
proteins and thus help conserve volume inside the catheter [135, 136]. Ringer acetate-like T1 
solution was used in the other catheters.  
The results of our study showed stable values for the parameters measured during the 
monitoring time, given that no manipulations of the liver or vascular clamping manoeuvres 
were carried out. The average levels measured by the 100kDa catheter perfused with Ringer 
like solution (100R) for glucose, glycerol and lactate tended to be higher as compared to the 
other catheters, although this difference was not statistically significant. Pyruvate 
measurements were however significantly higher in the 100R catheter when compared to the 
20R1 catheters (P<001). This could be because of volume loss in or higher recovery of the 
100R catheter. The 100V catheter however measured the four molecules comparably to the 
20-kDa catheters perfused with Ringer acetate-like T1 solution. It can thus be concluded that 
when using microdialysis catheters with 100 kDa cut-off for the measurement of small 
molecules in hepatic microdialysis, a high osmolality solution (Voluven) should be used as 
perfusate. 
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6.3 PAPER III 
Hepatic microdialysis has been used extensively in the setting of both liver resection surgery 
and transplantation [113, 114, 126, 134, 137]. Although an invasive method, its safety has 
been established and it has a very low complication rate. There are a few problems associated 
with the method which have prevented its widespread clinical application for postoperative 
monitoring. Most patients find the catheter to be uncomfortable and are disturbed by the 
hourly sampling especially during night time.  
We hypothesized that placing an intravascular microdialysis catheter with the tip in the 
hepatic vein would be theoretically as close to the hepatic interstitial compartment as 
possible. This could be done relatively non-invasively using the transjugular approach and 
advancing the microdialysis catheter as far as it would go into the middle hepatic vein using 
techniques used for placement of TIPS (Transjugular Intrahepatic Portosystemic Shunt) 
creation and HVPG (Hepatic venous pressure gradient) measurement [138, 139]. This would 
circumvent some of the issues discussed above and also the catheter could be replaced easily 
if needed. Conceptually, the microdialysis catheter placed in the hepatic vein, would sample 
blood directly leaving the liver, which in terms of composition should be as close to the 
hepatic interstitium that an intrahepatic microdialysis catheter samples. Several studies have 
proven the technical feasibility of intravascular microdialysis and results have been validated 
[140-142]. We devised an animal model of hepatic arterial ischemia comparing hepatic vein 
microdialysis and intrahepatic microdialysis for the monitoring of the metabolites, glucose, 
lactate, pyruvate and glycerol. 
Analysis of the microdialysis data from the intrahepatic catheters showed that glucose, 
lactate, glycerol levels and the L/Pr after an initial rise, continued to decline despite persistent 
clamping similar to findings of a study previously published by us [125]. This can be 
explained by a possible increase in oxygen extraction from portal venous blood by the 
hepatocytes. An interesting finding was that pyruvate levels in the subcutaneous catheter 
increased significantly during clamping but declined in the liver suggesting a possible 
systemic hypermetabolism as a result of hepatic ischemia. 
Glucose, glycerol, lactate and pyruvate and the calculated L/Pr levels remained stable 
throughout the experiment in the hepatic vein catheter. None of the changes in response to 
hepatic arterial clamping seen in the intrahepatic and subcutaneous catheters were registered 
in the hepatic vein catheter. It could be that in fact the tip of the hepatic vein catheter was too 
far from the interstitium resulting in a “dilution effect” or that the composition of the hepatic 
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venous blood is not comparable to that of the interstitium as hypothesized. Also, the recovery 
of metabolites could be reduced due the hepatic venous system being a “high flow” one. The 
recovery could be improved by increasing membrane length or adjusting the perfusion flow 
rate [115, 143, 144]. Thus, although hepatic vein microdialysis as a concept was an 
interesting idea, it could not in this study be used with equivalent results as standard 
intrahepatic microdialysis. Technical refinements could make it a feasible concept in the 
future.  
 
6.4 PAPER IV 
In this study we used PTC for a fixed period of time to establish controlled experimental 
conditions to study the effects of warm I/R injury in the human liver. The scope of the study 
was broad in that we studied ultrastructural changes using EM and in addition even redox 
enzyme systems with purported roles in I/R injury. Given that PTC is routinely performed 
usually for not more than 20 minutes, ethical considerations did not permit longer ischemia 
times which would have been desirable. The limitations notwithstanding, this study gives us a 
valuable information to further the understanding of hepatic I/R injury.  
The most striking finding of this study was the disruption of the LSEC post-ischemia seen on 
EM. This loss was quantitatively significant as seen on morphometric analysis. This goes 
against the conventional understanding that hepatocytes are more susceptible to warm I/R 
injury and LSECs to cold [9, 71]. However, LSEC death preceding that of hepatocytes has 
been reported in warm I/R injury too [145]. Apart from the fact that LSECs bore the major 
impact of the ischemic insult, another remarkable finding was the formation of pseudopod-
like projections from the LSEC surface on reperfusion. This was interpreted as a reactivation 
or reattachment of the LSECs. This finding was seen early and in 9 of 11 patients suggesting 
a reversibility of LSEC damage when the magnitude of ischemia is limited. Similar findings 
had been reported in cold ischemia [146]. Due to the short duration of the experiment and the 
fixed time-points of biopsy acquisition, the later phases of reperfusion injury could not be 
studied. 
The hepatocyte morphology seemed however remarkably well preserved as a response to 
warm I/R injury in this study, consistent with previous reports of intermittent PTC [147]. 
There was however, a loss of microvilli in the space of Disse after PTC and some had 
condensed nuclear chromatin. Additionally, the hepatic mitochondria were dilated and 
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showed the presence of crystalline inclusions which persisted after reperfusion. The nature of 
these crystalline inclusions usually seen in early alcohol and other liver diseases and aspirin 
toxicity is still unknown [148-151]. These inclusions could be an evolutionarily preserved 
adaptive response to ischemia. 
Gene expression analysis of TXN and GLRX isoforms and the associated redox proteins 
were not altered in this study. Immunogold results for TRX1 and GRX1 showed no changes 
in the hepatic GRX1 levels, but the levels of TRX1 present in the hepatocytes varied between 
the time points, suggesting a possible redistribution of the protein and thus a tentative role for 
the TRX family of proteins in warm I/R injury. This merits further investigation. 
 
6.5 PAPER V 
Only 1 of 45 (~2%) patients in our cohort developed HAT and thus describing the metabolic 
changes accompanying ischemic complications after LT was not feasible in this study. This 
patient however did not have L/Pr or lactate levels reaching the cut-offs defined by the study 
protocol to suggest ischemia. In case report 2 the patient reached cut-off levels but had no 
documented vascular complication. Analysis revealed that the rise in L/Pr in both patients 
was due to stable lactate levels and decreasing pyruvate and was followed by decreasing L/Pr 
as a result of increasing lactate and pyruvate levels suggestive of hypermetabolism. 
We analyzed the events of protocol-defined L/Pr rise in our study. Of a total of 44 such 
events in 24 patients, 26 (59%) had decreasing lactate and pyruvate levels during the episodes 
with faster decrease in pyruvate. This suggests recovery of metabolism in the transplanted 
liver rather than ongoing ischemia with a faster rate of metabolism of pyruvate. This 
preferential metabolism of pyruvate may be due to the fact that it can regulate its own 
metabolism and that there are more pathways for its metabolism [152]. In 10 patients (23%) 
with raised L/Pr, both lactate and pyruvate levels rose. The rising pyruvate makes ischemia 
unlikely and indicates a higher rate of lactate accumulation than pyruvate suggestive of 
hypermetabolism. Eighteen percent of the events (8 of 44) with increased L/Pr were 
accompanied by an increase in lactate and a decrease in pyruvate. Furthermore 17% of 
patients had L/Pr and lactate above the cut-off levels suggested by Haugaa et al. [126]. None 
of these patients had any clinical or radiological signs of or diagnosed ischemic 
complications. The possibilities are that the raised L/Pr was due to reasons other than graft 
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ischemia or that there indeed occurred ischemic events, but they were of no clinical 
significance as the clinical course continued uneventfully.  
Glucose metabolism in the liver is complex and differs fundamentally from other tissues. The 
liver enzymes involved in glucose metabolism are uniquely sensitive and the liver responds 
rapidly to ischemia and decreased glucose supply. The metabolic patterns detected by 
microdialysis in the post-LT phase probably reflect the effects of primary I/R injury on 
enzyme activity regulating glucose metabolism in the liver and the recovery of the metabolic 
machinery after LT. Intrahepatic L/Pr as an independent variable measured by microdialysis 
is a product of the complex metabolic interplay occurring in the liver and systemically in the 
early post-transplant phase. In our study using the suggested cut-off levels resulted in far too 
many false positives and L/Pr is thus not a reliable or specific marker of clinically significant 
ischemic complications post-LT. 
 
6.6 PAPER VI 
Rejection is not an instantaneous phenomenon and develops over time. Relative changes of 
metabolites measured by microdialysis over time more accurately reflect changes in the 
interstitium as compared to absolute values [144, 153]. In this study we have used AUC 
values for 12-hour intervals for the parameters glucose, lactate, pyruvate, glycerol and the 
L/Pr. 
Analysis of the microdialysis data shows that in the first 12 hours post-LT, patients who 
developed ACR had higher levels of intrahepatic L/Pr as compared to those without rejection. 
Logistic regression showed L/Pr AUC to be the only parameter in the first 12 hours post-LT 
to be associated with rejection. This finding suggests that grafts that develop ACR suffered 
greater primary I/R injury during storage and transplantation which is inherent to the 
transplant procedure [5]. This injury is seen only in the metabolic parameters and not in the 
time-zero biopsy. It is known that L/Pr decreases in the early post-LT phase, and in this 
cohort similar patterns were noted indicating a recovery from ischemia [113]. Additionally, in 
the rejection group, intrahepatic glucose levels were lower on day 2 after transplantation 
indicating a slower recovery of the gluconeogenetic pathway consequent to ischemia. 
Primary I/R injury to the graft before and during the transplant is an independent predictor of 
poor outcome after LT and has been linked to the development of rejection [154-157]. Our 
data supports this association. 
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On day 3 after LT, intrahepatic lactate and pyruvate levels were higher in patients who 
developed ACR. This could be the consequence of post-ischemic-hypermetabolism or the 
result of increased aerobic glycolysis due to lymphocyte activation as suggested by Haugaa et 
al. [126, 158, 159]. It could also be that the glucose produced as a result of ischemia induced 
glycogenolysis in the hepatocytes cannot enter the citric acid cycle at the rate of production 
and is thus converted to pyruvate and lactate, leading to higher levels on day 3. Glycerol 
levels showed no increase as would be expected in the patients who developed ACR and it 
could be that if microdialysis had been carried out for a longer period this would have been 
observed, but this was not practically possible.  
In the modern practice of LT, patients are discharged by postoperative day 8 to 10 and it is 
very hard to justify long periods of microdialysis monitoring. Consequently its use has not 
been introduced in the standard post-transplant monitoring protocol. Furthermore, it is 
evident that the interpretation of microdialysis results in the setting of LT is extremely 
challenging due to the complexity of the metabolic state of the post-transplant liver. Indeed, 
microdialysis monitoring following LT may detect some of the metabolic events that precede 
ACR but maybe not rejection itself. Devising strategies to attenuate the duration and severity 
of primary I/R injury to the liver graft may help to reduce the impact of ACR.  
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7 CONCLUSIONS 
This thesis allows the following conclusions to be made: 
 
Microdialysis allows monitoring of intrahepatic metabolism during liver resection surgery 
and is easy to use in humans. 
 
Warm ischemia-reperfusion injury induced by portal triad clamping is associated with 
considerable alterations with hepatic anaerobic metabolism, increased glycogenolysis, and 
cellular membrane damage. 
 
Microdialysis catheters with membrane cut-off of 100 kDa can be used equally as 20 kDa 
catheters in intrahepatic microdialysis for the monitoring of glucose, glycerol, lactate and 
pyruvate, and lactate/pyruvate ratio if a high osmotic solution such as Voluven is used as the 
perfusion fluid. It may be possible to monitor larger molecules using microdialysis with 
100kDa catheters without affecting the monitoring of small molecules. 
 
Hepatic vein microdialysis cannot be used equally as compared to direct intrahepatic 
microdialysis for the monitoring of glucose, glycerol, lactate and pyruvate. 
 
The major impact of hepatic warm I/R injury induced by portal triad clamping is borne by the 
sinusoidal endothelial cells with detachment and reactivation at ischemia and reperfusion, 
respectively. Hepatocyte morphology is well preserved apart from crystalline inclusions in 
the mitochondria. In situ protein observations suggest a tentative role for the thioredoxin 
family of proteins in liver ischemia-reperfusion injury 
 
Using microdialysis as a monitoring tool, an increase in the intrahepatic lactate/pyruvate ratio 
is not necessarily indicative of ischemic complications and may be raised in the absence of 
clinically significant ischemia in the liver early after transplantation. 
 
The metabolic patterns detected by microdialysis early after liver transplantation indicate a 
possible relation between primary ischemia-reperfusion injury and the development of acute 
cellular rejection.  
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8 FUTURE PERSPECTIVES 
The full potential of microdialysis as a clinical monitoring tool in liver resection surgery and 
transplantation has not been fully realized. Whether it is due to the complexity of the liver’s 
metabolic machinery or need for better refinement of the technique merits further research. 
Microdialysis can be used to study the hepatic response to not only I/R injury but also to 
investigate other conundrums like liver regeneration. To this end studies monitoring 
inflammatory markers, ROS, NO and gene products can add to the current knowledge with 
possible implications for clinical practice. Also, the use of large pore microdialysis catheters 
makes possible the study of bigger molecules. 
In our study investigating the ultrastructural changes associated with warm I/R injury, two 
striking findings were the hepatocyte mitochondrial crystalline inclusions and the apparent 
LSEC reactivation on reperfusion. Studies to further investigate these findings and shed light 
on their significance would be very valuable. Indeed, the LSEC reactivation occurs very early 
during reperfusion, probably indicating a key role for this cell type in the liver’s tolerance to 
ischemia and possibly other insults.  
Complementary to the EM study on liver resection patients, a similar study in the transplant 
setting would be extremely interesting but a logistically difficult one to perform. Apart from 
the ultrastructural findings, we would even be better able to study the role of the redox 
enzyme systems in I/R injury. The longer duration of I/R injury during LT would make it 
feasible to study changes at the gene expression level. 
The concept of hepatic vein microdialysis could be taken further by employing the TIPS 
technique to place the transjugular microdialysis catheter with the tip directly in the liver to 
get an intraparenchymal liver monitoring. However, the technicalities and risks with this 
approach need to be evaluated first. 
Lastly, the findings of our study on rejection suggested a possible link between primary I/R 
injury and the development of ACR. This association merits further investigation due to its 
immense implications for the clinical practice of liver transplantation.  
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Blödning är en av de vanligaste och allvarligaste komplikationerna i samband med 
leverkirurgi, då delar av levern tas bort. I samband med leveroperationer strävar man efter att 
minska blödningen så mycket som möjligt. Det vanligaste sättet att göra detta är att stänga av 
leverns blodflöde under tiden delningen av levervävnaden pågår. Dessa och andra 
intraoperativa tekniker vid leverkirurgi orsakar förändringar i leverns ämnesomsättning och 
vävnadskada i levern (s.k. ischemi-reperfusionsskada; I/R skada). Levertransplantation 
medför att organet är utan blod under en tidsperiod. När levern sedan opereras in i kroppen 
och blodflödet återställs kan ytterligare skada ske. I/R skada påverkar direkt leverns viabilitet 
och kan ge upphov till alltifrån organdysfunktion till livsfarlig leversvikt. Effekterna av I/R 
skada på leverns ämnesomsättning samt på mer subtila funktioner är ofullständigt studerade. 
Mikrodialys är en metod för att mäta olika ämnen direkt i vävnaden. Oftast mäts metaboliter i 
kolhydrat- och fettomsättning, såsom glukos, laktat, pyruvat och glycerol. 
I vår första studie undersöktes metabola förändringar i lever med mikrodialys hos patienter 
som genomgick leverkirugi. Blodflödet till levern stängdes av i 20 minuter och mikrodialys 
genomfördes. Resultaten visar ökade nivåer glukos, laktat, glycerol och ökad laktat/pyruvat-
kvot (L/Pr) i samband med blodflödesavstängningen, vilket tyder på betydande 
vävnadsskada. 
Vår andra och tredje studie är experimentella grisstudier med mikrodialys. I ena studien 
jämfördes två mikrodialyskatetrar med olika membranstorlek (20 och 100kDa). Vi kunde 
påvisa att 100 kDa katetrar var likvärdiga som 20 kDa katetrar för mätning av små molekyler. 
I den andra studien undersöktes huruvida en mikrodialyskateter som placerats i levervenen 
gav likvärdig mätning som mikrodialyskateter som placerats i levervävnaden. Studien visar 
att intravenös mikrodialys inte ger samma resultat som direkt mikrodialys i levern. 
I vår fjärde studie studerades förändringar i levervävnad med olika tekniker hos patienter som 
genomgick leverkirurgi.  Leverbiopsier togs vid tre tidpunkter: före och efter 
blodflödesavstängningen samt efter att blodflödet återställts. Vävnadsproverna studerades 
med elektronmikroskopi samt analyser för protein- och genuttryck. Vi kunde observera 
morfologiska förändringar främst i celler som omger blodkärl runt levercellerna. 
Levercellerna klarade sig ganska bra utan större tecken till skada. Ingen påverkan på 
redoxenzymer kunde ses under studietiden. 
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Studie 5 och 6 utfördes på patienter som genomgick levertransplantation. De övervakades 
med mikrodialys postoperativt. Tidigare studier har visat att L/Pr är en känslig markör vid 
vävnadsischemi.  Vi kunde inte påvisa något samband mellan ökad L/Pr och 
kärlkomplikationer efter transplantation. Vi studerade också sambandet mellan tidiga 
metabola förändringar i den transplanterade levern och senare utveckling av akut 
avstötningsreaktion. Hos patienter som utvecklade akut avstötning efter levertransplantation 
sågs högre L/Pr under de första 12 timmarna efter transplantationen. Detta tyder på ett 
samband mellan primär I/R skada och akut avstötning efter levertransplantation. 
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